Bronchoscopic Lung Ablation of Small Thoracic Tumors: the Blastt Registry

Not yet recruiting

• Conditions: Thoracic Tumors

• Registration Number: NCT06840288
• Lead Sponsor: M.D. Anderson Cancer Center

Brief Summary

To aggregate, integrate, and analyze data facilitating the study of MD Anderson patients with a known diagnosis of lung cancer or metastases to the lungs who undergo robotic assisted bronchoscopic ablation of peripheral tumors.

Detailed Description

A. To aggregate, integrate, and analyze data facilitating the study of MD Anderson participants with a known diagnosis of lung cancer or metastases to the lungs who undergo robotic assisted bronchoscopic ablation of peripheral tumors.

B. To assess the intra-operative, peri-operative, and long-term safety outcomes of robotic assisted bronchoscopic ablation of peripheral lung tumors.

C. To evaluate different oncologic outcomes including local tumor progression (LTP) by RECIST criteria, local tumor progression free survival (LTPFS), progression free-survival (PFS), disease (cancer) specific survival (DSS), and overall survival (OS).

D. To provide a deeper understanding of the evolution of radiographic findings of bronchoscopically ablated lung tumors over time.

E. To evaluate tumor and participant-related risk factors that may be associated with safety (bleeding, pneumothorax, and local infection) and oncologic outcomes (LTPFS, PFS, DSS, and OS).

Study Timeline

• Status Verified: 2025-02
• Study First Submitted: 2025-02-17
• Study First Submitted QC: 2025-02-17
• Last Update Submitted: 2025-02-17
• Study First Posted: 2025-02-21
• Last Update Posted: 2025-02-21
• Study Start: 2025-08-31
• Primary Completion: 2034-12-31
• Study Completion: 2036-12-31

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 250

Inclusion Criteria

• MD Anderson participants (defined as those with an MD Anderson Medical Record Number) with peripheral lung tumors (primary or metastatic) that have been or will be ablated via robotic bronchoscopy.

Exclusion Criteria

• Patient with planned bronchoscopic ablations of peripheral lung tumors that were aborted for technical reasons (ablation was not completed).

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To aggregate, integrate, and analyze data facilitating the study of MD Anderson patients with a known diagnosis of lung cancer or metastases to the lungs who undergo robotic assisted bronchoscopic ablation of peripheral tumors.	Through study completion, an average of 1 year.

Trial Locations

Locations (1)

MD Anderson Cancer Center; 🇺🇸 Houston, Texas, United States